Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants

By SquaredTown on March 30, 2026

Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants

Investment accelerates U.S. rollout of a scalable, at-home brain neuromodulation therapy for patients with depression and inadequate response to at least one antidepressant CORAL SPRINGS, Fla., March 30, 2026 /PRNewswire/ -- Neurolief, a medical technology company developing...

Read More